Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 15

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 15
---
isable for a three-year period from the date of the issuance at a per share exercise price of $0.80. We raised aggregate gross
proceeds of $2,790 thousands from the First Private Placement Offering and issued an aggregate of 6,975,000 shares of Common stock and
warrants to purchase 3,562,500 shares of Common Stock to qualified investors in this First Private Placement Offering.

In addition, between June and December 2021, we
received in escrow an aggregate of $950 thousands as subscription proceeds of a contemplated investment in the Company by certain qualified
investors and $250 thousands as subscription proceeds to an unrelated Israeli entity engaged in the treatment of addiction and related
mental disorders with whom the Company was then considering a business combination. Pursuant to the subscription agreements executed by
these investors and in accordance with their instructions and consents, the escrowed funds were released to the Company on November 14,
2023, upon the Company’s entering into the Share Exchange Agreement, and on that date we issued to these investors in the aggregate
3,000,000 shares of the Common stock and warrants to purchase 1,500,000 shares of our Common Stock on the same terms as the terms of the
First Private Placement Offering. In December 2023, our board decided to extend the exercise period of all of the outstanding warrants
through December 1, 2026.

<div align='center'>2</div>

Between April and December 2023, the Company conducted another private placement of units of its securities at $3.20 price per unit (the “Second Private Placement Offering”), offering to accredited investors units of securities, where each unit (a “Unit” and collectively the “Units”) comprised of (i) two (2) shares of the Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock exercisable until December 31, 2026, at a per share exercise price of $2.40. In consideration of proceeds in the amount of $4,631.25 thousands received from the subscribers in the Second Private Placement Offering, we issued to these investors an aggregate of 2,894,532 of the Company’s Common Stock and warrants to purchase an additional 1,447,266 shares of Common Stock. The shares of Common Stock sold in the above offerings and shares of Common Stock underlying the Investor Warrants issued by the Company to these investors are included in this registration statement of which